Genta Plans Genasense Confirmatory Trial In Treatment-Naive Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
With approval possible in June for relapsed or refractory leukemia, Genta is seeking a marketing partner for oblimersen.
You may also be interested in...
Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007
Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.
Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007
Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.
Genasense Injection To Go Before ODAC
Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncology Drugs Advisory Committee Sept. 6, the firm said July 27